Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Amgen Ltd
240 Cambridge Science Park, Milton Road, Cambridge, CB4 0WD
Telephone: +44 (0)1223 420 305
Fax: +44 (0)1223 426 314
Medical Information Direct Line: +44 (0)1223 436 441
Medical Information e-mail: gbinfoline@amgen.com
Customer Care direct line: +44 (0)808 0100 321
Medical Information Fax: +44 (0)1223 426 314

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 29/02/2012
PIL Vectibix

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 29/02/2012 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
Updated on 22/02/2012 and displayed until 29/02/2012
Reasons for adding or updating:
  • Change to side-effects
Updated on 22/11/2011 and displayed until 22/02/2012
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Changes to therapeutic indications
Updated on 03/06/2011 and displayed until 22/11/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 26/05/2010 and displayed until 03/06/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 12/05/2010 and displayed until 26/05/2010
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
Updated on 24/04/2009 and displayed until 12/05/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 22/01/2009 and displayed until 24/04/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
Updated on 27/08/2008 and displayed until 22/01/2009
Reasons for adding or updating:
  • Change to side-effects
  • Change to MA holder contact details
Updated on 21/04/2008 and displayed until 27/08/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 14/01/2008 and displayed until 21/04/2008
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  panitumumab